Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,383 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma.
Bang SM, Lee JH, Yoon SS, Park S, Min CK, Kim CC, Suh C, Sohn SK, Min YH, Lee JJ, Kim K, Seong CM, Yoon HJ, Cho KS, Jo DY, Lee KH, Lee NR, Kim CS; Korean Multiple Myeloma Working Party. Bang SM, et al. Among authors: lee nr, lee kh, lee jh, lee jj. Int J Hematol. 2006 May;83(4):309-13. doi: 10.1532/IJH97.A30512. Int J Hematol. 2006. PMID: 16757429
Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome.
Yang DH, Kim WS, Kim SJ, Bae SH, Kim SH, Kim IH, Yoon SS, Mun YC, Shin HJ, Chae YS, Kwak JY, Kim H, Kim MK, Kim JS, Won JH, Lee JJ, Suh CW. Yang DH, et al. Among authors: lee jj. Biol Blood Marrow Transplant. 2009 Jan;15(1):118-25. doi: 10.1016/j.bbmt.2008.11.010. Biol Blood Marrow Transplant. 2009. PMID: 19135950 Free article.
Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry.
Kim SJ, Kim K, Kim BS, Jo DY, Kang HJ, Kim JS, Mun YC, Kim CS, Sohn SK, Eom HS, Kwak JY, Shim H, Yoon HJ, Jin JY, Min CK, Shin H, Won JH, Lee JJ, Kwon JH, Joo YD, Do YR, Kim SH, Oh S, Suh C, Lee J, Yoon SS, Kim MK, Bang SM, Ryoo HM, Kim BS, Kim H, Kim HJ, Kim YS, Park CW, Lee GW, Shin HJ, Park SK, Park JS, Kim HY, Lee DS, Lee JH; Korean Multiple Myeloma Working Party. Kim SJ, et al. Among authors: lee j, lee ds, lee jh, lee jj, lee gw. Acta Haematol. 2009;122(4):200-10. doi: 10.1159/000253027. Epub 2009 Oct 29. Acta Haematol. 2009. PMID: 19887776
Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
Kim YK, Sohn SK, Lee JH, Yang DH, Moon JH, Ahn JS, Kim HJ, Lee JJ; Korean Multiple Myeloma Working Party (KMMWP). Kim YK, et al. Among authors: lee jh, lee jj. Ann Hematol. 2010 May;89(5):475-82. doi: 10.1007/s00277-009-0856-x. Epub 2009 Nov 18. Ann Hematol. 2010. PMID: 19921192 Clinical Trial.
Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia.
Bang SM, Seo JW, Park KU, Kim SJ, Kim K, Kim SH, Cho SR, Kim HC, Song J, Kim JS, Kim KH, Lee JH, Lee JJ, Shin MG, Suh C, Chi HS, Oh DY, Won JH, Kim HJ, Yoon SS, Lee DS; Korean Multiple Myeloma Working Party (KMMWP). Bang SM, et al. Among authors: lee ds, lee jh, lee jj. Cancer Genet Cytogenet. 2010 Mar;197(2):117-21. doi: 10.1016/j.cancergencyto.2009.11.008. Cancer Genet Cytogenet. 2010. PMID: 20193844
Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study.
Yang DH, Kim YK, Sohn SK, Chung JS, Joo YD, Lee JH, Lee JL, Ahn JS, Moon JH, Shin HJ, Choi YJ, Lee WS, Kim HJ, Lee JJ; Korean Multiple Myeloma Working Party. Yang DH, et al. Among authors: lee ws, lee jh, lee jj, lee jl. Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):62-7. doi: 10.3816/CLML.2010.n.007. Clin Lymphoma Myeloma Leuk. 2010. PMID: 20223731 Clinical Trial.
Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
Lee SS, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, Do YR, Jin JY, Kang HJ, Lee GW, Lee MH, Shim H, Kim K, Yoon SS, Bang SM, Kim HY, Lee JJ, Park J, Lee DS, Lee JH; Korean Multiple Myeloma Working Party. Lee SS, et al. Among authors: lee mh, lee ds, lee jh, lee gw, lee jj. Ann Hematol. 2010 Sep;89(9):905-12. doi: 10.1007/s00277-010-0943-z. Epub 2010 Mar 27. Ann Hematol. 2010. PMID: 20349060 Clinical Trial.
5,383 results